Suppr超能文献

利用双连接酶招募通过异三价靶向嵌合体增强蛋白质降解。

Leveraging Dual-Ligase Recruitment to Enhance Protein Degradation via a Heterotrivalent Proteolysis Targeting Chimera.

作者信息

Bond Adam G, Muñoz I Ordoño Miquel, Bisbach Celia M, Craigon Conner, Makukhin Nikolai, Caine Elizabeth A, Nagala Manjula, Urh Marjeta, Winter Georg E, Riching Kristin M, Ciulli Alessio

机构信息

Centre for Targeted Protein Degradation, School of Life Sciences, University of Dundee, 1 James Lindsay Place, Dundee DD1 5JJ, U.K.

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences Vienna 1090, Austria.

出版信息

J Am Chem Soc. 2024 Dec 11;146(49):33675-33711. doi: 10.1021/jacs.4c11556. Epub 2024 Nov 28.

Abstract

Proteolysis targeting chimera (PROTAC) degraders are typically bifunctional with one E3 ligase ligand connected to one target protein ligand via a linker. While augmented valency has been shown with trivalent PROTACs targeting two binding sites within a given target protein, or used to recruit two different targets, the possibility of recruiting two different E3 ligases within the same compound has not been demonstrated. Here we present dual-ligase recruitment as a strategy to enhance targeted protein degradation. We designed heterotrivalent PROTACs composed of CRBN, VHL and BET targeting ligands, separately tethered via a branched trifunctional linker. Structure-activity relationships of 12 analogues qualifies AB3067 as the most potent and fastest degrader of BET proteins, with minimal E3 ligase cross-degradation. Comparative kinetic analyses in wild-type and ligase single and double knockout cell lines revealed that protein ubiquitination and degradation induced by AB3067 was contributed to by both CRBN and VHL in an additive fashion. We further expand the scope of the dual-ligase approach by developing a heterotrivalent CRBN/VHL-based BromoTag degrader and a tetravalent PROTAC comprising of two BET ligand moieties. In summary, we provide proof-of-concept for dual-E3 ligase recruitment as a strategy to boost degradation fitness by recruiting two E3 ligases with a single degrader molecule. This approach could potentially delay the outset of resistance mechanisms involving loss of E3 ligase functionality.

摘要

蛋白酶靶向嵌合体(PROTAC)降解剂通常是双功能的,一个E3连接酶配体通过一个连接子与一个靶蛋白配体相连。虽然已经证明,三价PROTAC靶向给定靶蛋白内的两个结合位点或用于招募两个不同的靶标时,可以增加价态,但尚未证明在同一化合物中招募两个不同E3连接酶的可能性。在此,我们提出双连接酶招募作为一种增强靶向蛋白降解的策略。我们设计了由CRBN、VHL和BET靶向配体组成的异三价PROTAC,它们通过一个分支三功能连接子分别连接。12种类似物的构效关系表明AB3067是最有效、降解BET蛋白最快的降解剂,且E3连接酶交叉降解最小。在野生型、连接酶单敲除和双敲除细胞系中的比较动力学分析表明,AB3067诱导的蛋白泛素化和降解是由CRBN和VHL以累加方式促成的。我们通过开发一种基于CRBN/VHL的异三价BromoTag降解剂和一种包含两个BET配体部分的四价PROTAC,进一步扩大了双连接酶方法的范围。总之,我们为双E3连接酶招募提供了概念验证,这是一种通过用单个降解剂分子招募两个E3连接酶来提高降解适应性的策略。这种方法可能会延迟涉及E3连接酶功能丧失的抗性机制的出现。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/1c646c523191/ja4c11556_0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验